Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers

NCT01766219 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT01766219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01766219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2013
Completion date
May 18, 2018
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult primary cholangiocellular carcinoma, advanced adult primary liver cancer, cholangiocarcinoma of the extrahepatic bile duct, cholangiocarcinoma of the gallbladder, localized unresectable adult primary liver cancer, metastatic extrahepatic bile duct cancer, recurrent adult primary liver cancer, recurrent extrahepatic bile duct cancer, unresectable extrahepatic bile duct cancer